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It is generally accepted that the direct interaction between adhesion
molecules on the surfaces of inflammatory cells and vascular
endothelium is thought to be necessary for cellular infiltration at the
sites of inflammation (Roitt et al, 1993). In addition, ICAM-1 is
normally present on endothelium and is known to be present in
macrophages, fibroblasts, epithelial cells, lymphocytes and follic-
ular dendritic reticulum cells (Rothlein et al, 1986; Koch et al,
1991). It is an inducible ligand for lymphocyte function-associated
antigen 1 (LFA-1), and heavily influences cell–cell interactions in
inflammatory and immune responses (Smith and Thomas, 1990).
This interaction is also implicated in the various stages of tumour
progression and metastasis (McCarthy et al, 1991). Circulating
ICAM-1 in serum has been shown with elevated levels in several
diseases (Rothlein et al, 1991; Seth et al, 1991), and higher levels
associated with metastasis, tumour spread, and poor prognosis in
gastrointestinal cancers (Tsujisaki et al, 1991), melanoma
(Kageshita et al, 1992) and Hodgkin’s disease (Pizzolo et al, 1993).
E-selectin, commonly known as endothelial leucocyte adhesion
molecule-1 or ELAM-1, appears to be transiently endothelium
specific in its expression, mediating neutrophil, monocyte and
memory T-cell adhesion (Bevilacqua et al, 1993). VCAM-1 is also
induced on endothelium, mediating adhesion of lymphocytes and
monocytes; in addition, it is expressed in macrophages, follicular
dendritic cells and neural cells (Rice et al, 1991; Birdsall et al,
1992). VCAM-1 and E-selectin may be involved in metastasis by
mediating melanoma cells (Rice and Bevilacqua, 1989) and colon
carcinoma cells (Lauri et al, 1991) to endothelium. From the study
by Wenzel et al (1995), it suggests that the Sialyl Lewisx endothe-
lial-selectin ligand interaction may be important in facilitating head
and neck squamous cell carcinoma (HNSCC) cells to adhere during
metastasis. As reported elsewhere, soluble forms of these mole-
cules are associated with human malignancies (Banks et al, 1993).
In light of the above development, this study examines the
concentration of circulating ICAM-1, E-selectin and VCAM-1 in
nasopharyngeal carcinoma, oral carcinoma and laryngeal carci-
noma and correlates their levels with disease status.
MATERIALS AND METHODS
Subjects
Patients with nasopharyngeal carcinoma (n = 30), oral carcinoma
(n = 22) and laryngeal carcinoma (n = 22) were examined. Twenty
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Table 1 Clinical summary of control subjects and patients studied
Control subjects NPC OC LC
(n = 20) (n = 30) (n = 22) (n = 22)
Sex
Men 8 23 17 21
Women 12 7 5 1
Age (years)
Mean ± s.d. 38.3 ± 4.0 48.61 ± 12.4 50.3 ± 9.5 64.6 ± 8.6
Range 19–63 19–69 32–64 44–81
Stage I and II 13 14 12
Stage III and IV 17 8 10
NPC, nasopharyngeal carcinoma; OC, oral carcinoma; LC, laryngeal
carcinoma; s.d., standard deviation. Staging was performed according to
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people who received laryngomicrosurgery for vocal polyps or
nodules and without regional or systemic disorders were used as
control subjects. Informed consent was obtained from all subjects.
Table 1 summarizes the patients and control subjects studied
herein, including gender, age and staging of carcinomatous status.
The staging was according to the AJCC Staging System (1988).
Blood samples
Blood samples were obtained before definite treatment was begun.
Blood was centifuged at 1500 r.p.m. for 15 min, at room tempera-
ture. Finally, serum was separated and frozen until further use.
Immunoassay
The concentration of sICAM-1, sE-selectin and sVCAM-1 in serum
was determined by enzyme-linked immunoassay kits (ELISA) from
R&D Systems (Minneapolis, MN, USA), and were used according to
the manufacturer’s instructions. The sensitivities were 7 ng ml–1 for
sICAM-1, 2 ng ml–1 for sE-selectin and 100 ng ml–1 for sVCAM-1.
Statistical analysis
The statistical significance was evaluated with Student’s t-test. A
P-value of less than 0.05 was deemed statistically significant.
RESULTS
According to Table 2, sICAM-1, sE-selectin and sVCAM-1 in the
area of nasopharyngeal cancer, sE-selectin in oral cancer, and sE-
selectin and sVCAM-1 in laryngeal cancer are significantly higher
than those in control subjects, although the sICAM-1 in laryngeal
cancer is significantly lower.
According to the staging systems, the status of these malignan-
cies was divided into early (stage I and II) and late (stage III and
IV) stages. sICAM-1, sE-selectin and sVCAM-1 do not differ in
terms of concentrations between the early and the late stages of
nasopharyngeal, oral and laryngeal carcinoma (Table 3).
DISCUSSION
The cellular source and the mechanisms for releasing the soluble
components of these endothelial adhesion molecules, although not
well known, could involve either shedding or enzymatic cleavage
from endothelial cells, leucocyte surfaces or tumour cells. Previous
works have indicated that the cellular expression of ICAM-1 on
normal and malignant epithelial tissue including melanoma cell
lines (Natali et al, 1990; Becker et al, 1991; Giavazzi et al, 1992)
and renal cell lines (Tomita et al, 1990) can be augmented by g-
interferon (IFN-g), interleukin 1 (IL-1) and tumour necrosis factor
(TNF-a) (Maio et al, 1989; Vanky et al, 1990; Azuma et al, 1992).
Notably, TNF can cause the release of ICAM-1, VCAM-1 and E-
selectin from endothelial cells of human umbilical vein (Pigott et
al, 1992). IFN-g can also induce expression and shedding of ICAM-
1 from gastric cell lines (Harning et al, 1991). However, the clinical
significance and the interaction between these molecules still
remain relatively unknown. Yamamoto et al (1994) measured the
circulating ICAM-1 in the sera of oral diseases, indicating that the
circulating ICAM-1 was not elevated in the sera of oral squamous
cell carcinoma patients. Similarly, in this series, the circulating
ICAM-1 was not elevated in the sera of patients with oral cancer
and laryngeal cancer in this series. However, circulating ICAM-1,
E-selectin and VCAM-1 were elevated in the sera of patients with
nasopharyngeal carcinoma (NPC), i.e. a common human epithelial
carcinoma in South-East Asia. The discrepancy of the level of
soluble ICAM-1 among these three groups of patients of head
and neck carcinomas might be attributed to either the different
immunological reaction profiles or a cell-specific response.
According to previous investigators, soluble IL-2 receptor, IFN-g
and TNF-a were elevated in NPC patients (Hsu et al, 1991; Kuo
et al, 1994). These factors might contribute towards the cellular
expression and shedding of ICAM-1, E-selectin and VCAM-1 as
shown in these NPC patients.
VCAM-1 and E-selectin are largely absent on the endothelium
of normal tissue vessels (Kuzu et al, 1993). VCAM-1 is present on
lymphoid dendritic cells, some tissue macrophages and renal
parietal epithelium in addition to activated endothelial cells (Rice
et al, 1991). VCAM-1 might be involved in metastasis of
melanoma (Rice et al, 1989). Interestingly, elevated levels of
sVCAM-1 were noted in several human malignancies such as in
the ovary and breast, outside of the head and neck region (Banks et
al, 1993). Expression of E-selectin is endothelium-specific
(Bevilacqua and Nelson, 1993), and E-selectin-mediated adhesion
of colon carcinoma and head and neck squamous cell carcinoma
cells to endothelium is suggested to be associated with metastasis
(Lauri et al, 1991; Wenzel et al, 1995). Soluble E-selectin is evalu-
ated as a marker for endothelial damage after activation by
cytokines (Gearing and Newman, 1993), the levels are higher in
ovarian, breast and gastrointestinal cancers (Banks et al, 1993).
The increased levels of sE-selectin in the patients sera of NPC,
oral and laryngeal cancers in this series might be attributed to the
shedding of endothelially bound E-selectin in the tumour tissues.
Table 2 Serum adhesion molecule levels in three head and neck cancers
Control subjects NPC OC LC
(n = 20) (n = 30) (n = 22) (n = 22)
ICAM-1 215.4 ± 10.2a 269.9 ± 19.0* 219.0 ± 19.2 157.5 ± 12.6
E-selectin 41.7 ± 4.0 71.3 ± 5.3* 70.5 ± 12.1* 64.8 ± 9.2*
VCAM-1 837.0 ± 39.8 1168.9 ± 92.8* 985.0 ± 85.5 1155.2 ± 115.8*
NPC, nasopharyngeal carcinoma; OC, oral carcinoma; LC, laryngeal
carcinoma. aMean ± standard error mean (ng ml–1); *significantly higher than
in control subjects P < 0.05 by Student’s t-test.
Table 3 Comparison of serum levels of adhesion molecules between early
and late stages
ICAM-1 E-selectin VCAM-1
NPC
Stage I and II (n = 13) 252.5 ± 23.9a 70.0 ± 8.3 1188.5 ± 155.7
Stage III and IV (n = 17) 289.1 ± 29.2 72.3 ± 7.1 1154.0 ± 116.6
OC
Stage I and II (n = 14) 224.0 ± 19.5 65.1 ± 13.7 997.0 ± 93.7
Stage III and IV (n = 8) 208.9 ± 44.9 90.7 ± 23.6 918.6 ± 183.7
LC
Stage I and II (n = 10) 140.8 ± 15.9 62.5 ± 13.8 1284.0 ± 188.1
Stage III and IV (n = 12) 170.0 ± 18.2 66.8 ± 12.9 1132.5 ± 143.7
aMean ± standard error mean (ng ml–1); NPC, nasopharyngeal carcinoma;
OC, oral carcinoma; LC, laryngeal carcinoma.362 C-M Liu et al
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Thus, this E-selectin might be a potential marker for tumour inva-
siveness or angiogenesis in head and neck cancer.
The differences arising between the levels of sICAM-1,
sVCAM-1 and sE-selectin in these three head and neck cancers
might be attributed to the nature of the tumour, cytokines respon-
sible for adhesion molecule expression, shedding regardless of
whether they are tumour-derived or derived from surrounding host
tissues, and kinetics of expression and shedding.
The progression of a tumour from benign delimited prolifera-
tion to invasive and metastasic growth depends on angiogenesis,
enhanced extracellular matrix degradation via tumour- and host-
secreted proteases, tumour cell migration and modulation of
tumour cell adhesion. Each individual component is multifaceted
(Price et al, 1997). The fact that sICAM-1, sVCAM-1 and sE-
selectin did not significantly differ in terms of levels between early
and late stages of these three head and neck cancers accounts for
why these soluble adhesion molecules appear not to be the only
factor in their tumour progression.
Immunologically, shedding of adhesion molecules by activated
endothelial cells and tumour cells might not only block their
counter ligands on immunocompetent cells, but also allow the
tumour cells to escape from surveillance by cytotoxic T-cells and
natural killer cells, thereby promoting metastasis. These shedding
adhesion molecules might also prevent tumour cells from adhering
to endothelial cells during extravasation. Future investigations on
the function and interaction of these adhesion molecules may
clarify the mechanism of tumour progression and metastasis.
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